| Bioactivity | PBT434 is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 has the potential for the research of Parkinson’s disease (PD)[1]. |
| Invitro | PBT434 (0-20 µM；3 小时) 显着抑制铁产生的 H2O2，并显着降低 Fe 介导的 α-突触核蛋白聚集速率[1]。PBT434 (0-100 µM; 24 h) 对脑微血管内皮细胞没有细胞毒性作用[2]。PBT434 (20 µM; 24 h) 增加 hBMVEC 中总 TfR、Cp 蛋白水平的表达[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> PBT434 相关抗体: Cell Cytotoxicity Assay[2] Cell Line: |
| In Vivo | PBT434 (30 mg/kg；口服；每日一次，持续 21 天) 显着保留了 6-OHDA 毒模型中的神经元数量，并在 L-DOPA 模型中显示出明显更少的旋转，显着减少了 MPTP 模型中的 SNpc 神经元损失[ 1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 1232841-78-9 |
| Formula | C12H14BrCl2N3O2 |
| Molar Mass | 383.07 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Finkelstein DI, et al. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease. Acta Neuropathol Commun. 2017 Jun 28;5(1):53. [2]. Bailey DK, Clark W, Kosman DJ. The iron chelator, PBT434, modulates transcellular iron trafficking in brain microvascular endothelial cells. PLoS One. 2021 Jul 26;16(7):e0254794. |
PBT434
CAS: 1232841-78-9 F: C12H14BrCl2N3O2 W: 383.07
PBT434 is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 can be us
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.